nVerses Capital’s Regenxbio RGNX Stock Holding History

nVerses Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,400	Closed	-$35.7K	–	696
2024 Q3	$35.7K	Buy	3,400 +2,200	+183%	+$26.8K	0.02%	714
2024 Q2	$14K	Buy	+1,200	New	+$18.7K	0.01%	855

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

nVerses Capital's RGNX Position: Q4 2024 in Review

nVerses Capital sold out of Regenxbio (RGNX) in Q4 2024, closing a stake of 3,400 shares — an estimated $35.7K sold.

nVerses Capital first reported a position in RGNX in Q2 2024 and held it in 2 quarters. The position peaked at $35.7K in Q3 2024. 177 funds tracked by Wall St. Rank hold RGNX as of Q4 2024.

nVerses Capital reported no remaining Regenxbio position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 3,400 Regenxbio shares in Q4 2024, an estimated $35.7K.
nVerses Capital first reported a position in Regenxbio in Q2 2024 and held it in 2 quarters.
nVerses Capital's Regenxbio position peaked at $35.7K in Q3 2024.
177 funds tracked by Wall St. Rank held Regenxbio as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.